camostat mesylate Report issue

Small molecule Experimental
AACT ChEMBL Drug Central KEGG PubChem

Active Ingredient History

NOW
  • Now
Camostat is a serine protease inhibitor. Serine protease enzymes have a variety of functions in the body, and so camostat has a diverse range of uses. Camostat is approved in Japan for the treatment of chronic pancreatitis and postoperative reflux esophagitis. The oral proteolytic enzyme inhibitor has been on the market since 1985 under the trade name Foipan Tablets. The manufacturer is Ono Pharmaceutical. The drug is used in the treatment of some forms of cancer and is also effective against some viral infections, as well as inhibiting fibrosis in liver or kidney disease or pancreatitis.   Wikipedia

Chemistry

  • SMILES: CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(=N)N)cc2)cc1
  • InChIKey: XASIMHXSUQUHLV-UHFFFAOYSA-N
  • Mol. Mass: 398.42
  • ALogP: 1.39
  • ChEMBL Molecule:
    camostat  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

camostat | camostat mesilate | camostat mesylate | ni-03 | qau145

Organizations (34)

Research & Development (34)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (16)

Approved Indications (1)


 

Pancreatitis

Experimental Indications - Clinical Trial Phases 1-4 (15)


 

Bleeding Time (Phase 1/Phase 2)

Cardiovascular Diseases (Phase 1/Phase 2)

Coronavirus Infections (Phase 2)

COVID-19 (Phase 4)

Cystic Fibrosis (Phase 2)

Diabetes Mellitus (Phase 2)

Drug Therapy (Phase 2)

Esophagitis ()

Fontan Procedure (Phase 2)

Healthy Volunteers (Phase 1)

Hypertension (Phase 2)

Obesity (Phase 2)

Pancreatitis, Chronic (Phase 1/Phase 2)

Protein-Losing Enteropathies (Phase 2)

Severe Acute Respiratory Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 28
  • # of Trial Organizations: 34

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue